Efficacy of Gabapentin Enacarbil vs Placebo in Patients with Postherpetic Neuralgia and a Pharmacokinetic Comparison with Oral Gabapentin

Pain Medicine

Volumn 12, Issue 7, 2011, Pages 1098-1108

  Backonja, Miroslav M ^a   Canafax, Daniel M ^b   Cundy, Kenneth C ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b XenoPort Inc   (United States)

Author keywords

Gabapentin; Gabapentin Enacarbil; Neuropathic Pain; Pharmacokinetics; Postherpetic Neuralgia

Indexed keywords

GABAPENTIN; GABAPENTIN ENACARBIL; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; BLURRED VISION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; HEADACHE; HERPES ZOSTER; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MOOD; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP; STEADY STATE; TACHYCARDIA; TIMED DRUG RELEASE; TREATMENT OUTCOME;

EID: 79960365429     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01139.x     Document Type: Article

References (25)

1. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002;347:340-6.
2. Dworkin RH, Gnann JW Jr, Oaklander AL, etal. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain 2008;9(1 suppl 1):S37-44.
3. Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. Lancet 1994;343:1648.
4. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-4.
5. Backonja M, Serra J. Pharmacologic management part 1: Better-studied neuropathic pain diseases. Pain Med 2004;5(suppl 1):S28-47.
6. Johnson RW, Wasner G, Saddier P, Baron R. Post herpetic neuralgia: Epidemiology, pathophysiology and management. Expert Rev Neurother 2007;7:1581-95.
7. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998;280:1837-42.
8. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 2001;94:215-24.
9. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003;25:81-104.
10. Singh D, Kennedy DH. The use of gabapentin for the treatment of postherpetic neuralgia. Clin Ther 2003;25:852-89.
11. Miller R, Ewy W, Corrigan BW, etal. How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 2005;32:185-97.
12. Lockwood PA, Cook JA, Ewy WE, Mandema JW. The use of clinical trial simulation to support dose selection: Application to development of a new treatment for chronic neuropathic pain. Pharm Res 2003;20:1752-9.
13. Gidal BE, Radulovic LL, Kruger S, etal. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res 2000;40:123-7.
14. Neurontin (gabapentin). [Prescribing Information]. New York, NY: Pfizer Inc.; 2009.
15. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-81.
16. Bratten JR, Jones MP. Small intestinal motility. Curr Opin Gastroenterol 2007;23:127-33.
17. McLean MJ. Gabapentin. Epilepsia 1995;36(suppl 2):S73-86.
18. Cundy KC, Annamalai T, Bu L, etal. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther 2004;311(1):324-33.
19. Cundy KC, Branch R, Chernov-Rogan T, etal. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther 2004;311:315-23.
20. Cundy KC, Sastry S, Luo W, etal. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008;48:1378-88.
21. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 1997;48:332-8.
22. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human patients. 1996 Revision.
23. McNair DM, Lorr M. An analysis of mood in neurotics. J Abnorm Psychol 1964;69:620-7.
24. Lal R, Sukbuntherng J, Luo W, etal. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: A randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 2009;31:1776-86.
25. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-46.